Full Press Release Details
Radiopharm Theranostics Partners with Starpharma
on Research and Option Agreement to Develop a Novel Radiotherapy Asset
Program to incorporate Radiopharm's Theranostics'
radiopharmaceutical molecule with Starpharma's proprietary DEP platform technology to develop and manufacture a new drug conjugate
Sydney, Australia - September 30,
2025 - Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage
biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced
the signing of a research and option agreement with Starpharma (ASX: SPL, US OTC: SPHRY), to develop and manufacture a radiopharmaceutical
molecule utilising Starpharma's proprietary DEP platform technology. Starpharma will also grant Radiopharm an exclusive option
to license the asset developed through this collaboration, subject to successful development and manufacturing.
Radiopharm Theranostic's Chief Executive Officer, Riccardo
Canevari, commented:
"We are excited to collaborate with Starpharma to explore the
potential of combining Radiopharm's novel radiotherapeutic molecule with their cutting-edge DEP platform. This partnership
represents a strategic step forward in our mission to develop highly targeted and effective radiopharmaceuticals for cancer treatment."
Cheryl Maley, Starpharma Chief Executive Officer,
"This research and option agreement with
Radiopharm Theranostics is the first Star Navigator program to progress into a formal research collaboration, marking a key milestone.
We are excited by the opportunity to advance this partnership with Radiopharm and to continually demonstrate how Starpharma's DEP
platform can help shape the future of targeted cancer therapies."
Terms of the Research & Option Agreement
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
Starpharma (ASX: SPL, OTCQX: SPHRY) is an innovative
biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to
help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application
of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties-including
their size, structure, high degree of branching, polyvalency, and water solubility-are advantageous in medical and pharmaceutical
Starpharma's portfolio of dendrimer-based
products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research
collaborations, and three commercially marketed over-the-counter (OTC) products. For more information about Starpharma, visit www.starpharma.com
or connect with Starpharma on LinkedIn.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company
developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high
unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated
platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one
Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm
Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
CEO & Managing Director
Precision AQ (formerly Stern IR)
Follow Radiopharm Theranostics:
Website - https://radiopharmtheranostics.com/
InvestorHub - https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia